Reply to Commentary to Skudlik et al. (2023): why a scoping review and why only Germany? No … ← Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial SCANPatient: study protocol for a multi-centre, batched, stepped wedge, comparative effectiveness, randomised clinical trial of synoptic reporting of computerised tomography (CT) scans assessing cancers of the pancreas →